Suparna Banerjee*, Yeshwanth Mahesh*, Dhamodharan Prabhu, Kanagaraj Sekar, Prosenjit Sen (2023). Identification of potent anti-fibrinolytic compounds against plasminogen and tissue-type plasminogen activator using computational approaches. Journal of Biomolecular Structure and Dynamics: 1-19 

Yeshwanth Mahesh, Subbalakshmi AR, Mohit Kumar Jolly (2024). Feedback Loops in Gene Regulatory Networks and Cell-Cell Communication Networks: Drivers of Cancer Cell Plasticity. In Cancer through the Lens of Evolution and Ecology (pp. 50-57). CRC Press.

Kumar, A., Yeshwanth, M., Kumar, K., Panwar, J., Gupta, S. (2022). Functionalized Cu-based metal oxide nanoparticles with enhanced Cd+ 2 adsorption capacity and their ecotoxicity assessment by molecular docking. Journal of Environmental Management, 307, 114523. 

Shreya Sharma, Harsha Rani, Yeshwanth Mahesh, Mohit Kumar Jolly, Vijayalakshmi Mahadevan (2024) Loss of p53 epigenetically modulates epithelial to mesenchymal transition in colorectal cancer. Translational Oncology 43 : 101848.

Anil Kumar, Yeshwanth Mahesh, Jitendra Panwar, Suresh Gupta (2024). Remediation of multifarious metal ions and molecular docking assessment for pathogenic microbe disinfection in aqueous solution by waste-derived Ca-MOF. Environmental Science and Pollution Research : 1-23.

Kumar, A., Bisoi, A., Yeshwanth, M., Jujaru, M., Panwar, J., & Gupta, S. (2024). Unveiling dye adsorption capability of Moringa oleifera functionalized hybrid porous MOF-GO composites: In vitro and in silico ecotoxicity assessment via antibacterial and molecular docking studies. Environmental Science: Water Research & Technology. 

Srinivasulu Cheemanapalli, Chandrasekaran Palaniappan, Yeshwanth Mahesh, Yuvaraj Iyyappan, Suresh Yarrappagaari, Kanagaraj Sekar (2022). In Vitro and In Silico Perspectives to Explain Anticancer Activity of a Novel Syringic Acid Analog ((4-(1H-1, 3-benzodiazol-2-yl)-2, 6-dimethoxy phenol)) through Apoptosis Activation and NFkB Inhibition in K562 Leukemia Cells. Computers in Biology and Medicine, 106349. 

Srinath M*, Manas S*, Soundharya R*, Susmita M, Sauma Suvra M, Yeshwanth M, Aryamaan Saha, Mohit Kumar Jolly (2022). PD-L1 activity is associated with partial EMT and metabolic reprogramming in carcinomas. Current Oncology, 29.11 : 8285-8301.

Ayalur R S*, Sarthak S*, Prakruthi M, Shaurya G Vignesh A K, Yeshwanth M, Soundharya R, Isabelle M, Jason A. Somarelli, Mohit Kumar Jolly(2023). The ELF3 transcription factor is associated with an epithelial phenotype and represses epithelial-mesenchymal transition. Journal of Biological Engineering 17.1: 1-16.

Kathryn E. Ware, Beatrice C. Thomas, Pelumi Olawuni, Maya U. Sheth, Nathan Hawkey, Yeshwanth M, Brian C. Miller, Katherine J. Vietor, Mohit Kumar Jolly, So Young Kim, Andrew J. Armstrong, and Jason A. Somarelli (2023). A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer. Frontiers in Molecular Biosciences 10: 1104505.

Shinjinee Sengupta, Namrata Singh, Ajoy Paul, Debalina Datta, Debdeep Chatterjee, Semanti Mukherjee, Laxmikant Gadhe, Jyoti Devi, Yeshwanth Mahesh, Mohit Kumar Jolly, Samir Maji (2023). p53 amyloid pathology is correlated with higher cancer grade irrespective of the mutant or wild-type form. Journal of cell science, 136(17), jcs261017.

Suparna Banerjee*, Yeshwanth M*, Subhasis Mondal*, Subhojit Paul, Prosenjit Sen (2024). Discovery of novel small-molecule inhibitors against PD-L1: Its in silico and in vivo evaluation. (In preparation)

Yeshwanth M, Kanagaraj Sekar (2024). A unique class of dual inhibitors against protease and reverse transcriptase of HIV-1 & 2. (In preparation)

Chatterjee A, Paul S, Banerjee S*, Yeshwanth M*, Sen P (2024). Sunshinamide increases cellular ROS levels by targeting TrxR1 and Gpx4 to ER stress and ferroptosis mediated cell death in cancer cells. (In preparation)